Carmegliptin
Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC50 of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1, potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus.
For research use only. We do not sell to patients.
- CAS No.: 813452-18-5
- Formula: C20H28FN3O3
- Molecular Weight:377.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
DPP-4 6.8 nM (IC50) |
Carmegliptin potently inhibits human DPP-IV with an IC50 of 6.8 nM[1].
Carmegliptin (10 μM) is highly selective for human DPP-IV, with no significant off-target activity at 10 μM and > 100-fold selectivity over related proline-specific dipeptidyl peptidases[1].
Carmegliptin does not inhibit or induce CYP450 enzymes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | CL | Vss | T1/2 | F |
|---|---|---|---|---|---|---|
| Monkey2 | 1 mg/kg | i.v. | 8.5 mL/min/kg | 3.3 L/kg | 6.8 h | / |
| Monkey2 | 3 mg/kg | p.o. | / | / | / | 33 % |
| Rat2 | 1 mg/kg | i.v. | 24 mL/min/kg | 6.3 L/kg | 3.3 h | / |
| Rat2 | 3 mg/kg | p.o. | / | / | / | 28 % |
Carmegliptin (20 mg/kg; p.o.; daily; 7 days) improves insulin sensitivity via increased GIR and shows a trend toward reduced hepatic glucose production in insulin-resistant Zucker fatty (fa/fa) rats[1].
Carmegliptin (10 mg/kg; p.o.; single dose) produces a significant reduction in fasting blood glucose and reduces the oral glucose tolerance test AUC0-t by 30%[1].
Carmegliptin(3 mg/kg; p.o.; single dose) produces sustained plasma DPP-IV inhibition in non-diabetic cynomolgus monkeys, with 40% and 60% baseline activity remaining at 24 and 48 hours post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 813452-18-5
-
Molecular Weight 377.45
-
Formula C20H28FN3O3
-
SMILES
O=C(C1)N(C[C@H]1CF)[C@H]2CN3CCC4=CC(OC)=C(OC)C=C4[C@@]([H])3C[C@@H]2N
-
Synonyms
RO-4876904
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Boehringer M,et al. Pyrido [2,1-a] isoquinoline derivatives. US20040259903A1. 2004-12-23.
[2]. Mattei P, et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1109-13. [Content Brief]
[3]. Kuhlmann O, et al. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. J Drug Assess. 2014 Mar 3;3(1):28-37. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz